Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Nanoquantification of RUNX2 by a 1,1'-carbonyldiimidazole-diamond mediated sandwich assay for osteogenic differentiation.

Sun Q., Zhu W., Shi E., Bai M., Liu Z., Yang Z.

Laboratory Study on Autoimmune Research, published in Heliyon (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Heliyon (2024)
Country
England
Reported sample size
—
Source database
PubMed
PMID
38868000
PMCID
PMC11167296
DOI
10.1016/j.heliyon.2024.e31837

Abstract (original English)

Adipose tissue-derived stem cells (ADSCs) possess the capability to modulate the immune response and alleviate inflammation, rendering them a promising therapeutic option for various conditions, including autoimmune diseases, cardiovascular diseases, and tissue injuries. The osteogenic differentiation in ADSCs plays a pivotal role in fracture healing, bone growth, and the overall bone turnover process, governed by intricate interactions. Runt-related Transcription Factor 2 (RUNX2) is a key player in mineralized tissue generation and is typically found in the early stages of osteogenic differentiation. The objective of this study was to develop a high-affinity sandwich biosensor for the quantification of RUNX2. 1,1'-Carbonyldiimidazole-modified nanodiamond was immobilized on an amine-modified interdigitated electrode surface, followed by the use of a capture antibody to facilitate antigen interaction. A sandwich assay was conducted with the antibody, and the limit of detection for RUNX2 was calculated as 0.1 ng/mL, with a regression value (R 2 ) of 0.9914 over a linear range of 1-2000 ng/mL. Furthermore, biofouling experiments with a nonimmune antibody, BSA, and TNF-α did not yield any current responses, indicating the specific detection of RUNX2. Additionally, RUNX2-spiked serum exhibited an increasing current response at all concentrations, confirming the selective detection o

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research